Rilonacept

( DrugBank: Rilonacept / KEGG DRUG: Rilonacept )


5 diseases
IDDisease name (Link within this page)Number of trials
51Scleroderma1
84Sarcoidosis1
106Cryopyrin-associated periodic syndrome3
IDDisease name (Link within this page)Number of trials
107Juvenile idiopathic arthritis2
266Familial mediterranean fever1

51. Scleroderma


Clinical trials : 639Drugs : 551 - (DrugBank : 157) / Drug target genes : 135 - Drug target pathways : 222 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

84. Sarcoidosis


Clinical trials : 175Drugs : 189 - (DrugBank : 80) / Drug target genes : 74 - Drug target pathways : 177 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

106. Cryopyrin-associated periodic syndrome


Clinical trials : 56Drugs : 27 - (DrugBank : 7) / Drug target genes : 4 - Drug target pathways : 47 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

107. Juvenile idiopathic arthritis


Clinical trials : 477Drugs : 232 - (DrugBank : 53) / Drug target genes : 66 - Drug target pathways : 160 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

266. Familial mediterranean fever


Clinical trials : 35Drugs : 21 - (DrugBank : 7) / Drug target genes : 14 - Drug target pathways : 58 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries